FDC Limited's Timolol Maleate Ophthalmic Solution Recalled: Recurring Container Defects Impact US Supply
FDC Limited has initiated a Class II recall for 176,784 bottles of Timolol Maleate Ophthalmic Solution USP, 0.5%, distributed nationwide in the U.S. The recall, D-0642-2024, stems from defective containers preventing solution dispensing. This marks a recurring issue for FDC's Aurangabad facility, previously identified for similar container defects with the same product. Procurement and regulatory teams must assess supply continuity and FDC's quality control.
What the FDA Identified: Product Defect and Recall Scope
FDC Limited has initiated a voluntary Class II recall, identified as D-0642-2024, for 176,784 bottles of its Timolol Maleate Ophthalmic Solution USP, 0.5%. This action, reported on August 28, 2024, and initiated by the firm on August 12, 2024, addresses a critical product defect: patients are unable to dispense the solution from the bottle because the cap's spike is lodged in the product bottle's nozzle. This directly impacts patient access to medication, raising concerns for procurement directors and regulatory affairs heads regarding product efficacy and patient adherence. The affected product lots are 083K063, with an expiration date of October 31, 2025, and 083I091, expiring on August 31, 2025. The recall encompasses two packaging configurations: 5mL bottles (NDC 64980-514-05) and 10mL bottles (NDC 64980-514-01). The distribution pattern for these affected units is nationwide across the U.S.A., indicating a broad market exposure. For supply chain VPs, this widespread distribution necessitates immediate assessment of inventory levels across all distribution channels and a rapid execution of return logistics to minimize disruption and ensure patient safety. The Class II classification signifies that the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote, yet the functional failure to dispense is a significant concern for patient care.
FDC Limited's Aurangabad Facility: Production and Market Impact
The recalled Timolol Maleate Ophthalmic Solution USP, 0.5%, was manufactured by FDC Limited at its facility located in Waluj, Aurangabad, Maharashtra State, India. This facility serves as a critical manufacturing hub for generic ophthalmic prescription drugs destined for the U.S. market. The product is subsequently distributed in the U.S. by Rising Pharmaceuticals Inc, based in New Jersey, highlighting the intricate global supply chains involved in pharmaceutical delivery. For business development executives, this event underscores the inherent risks associated with reliance on single-source or concentrated manufacturing locations, particularly for essential medications. Timolol Maleate is a widely used beta-blocker indicated for the treatment of glaucoma and ocular hypertension, making its consistent availability crucial for patient health outcomes. The manufacturing defect at FDC Limited's Aurangabad site directly jeopardizes the supply stability of this essential ophthalmic solution in the U.S. market. Procurement directors must now scrutinize their supplier qualification processes for overseas manufacturers, focusing not only on API quality but also on the integrity of finished product packaging and dispensing mechanisms. The incident necessitates a review of contractual agreements with manufacturers and distributors to ensure clear accountability for such quality failures and to mitigate financial and reputational damage.
Supply Chain Vulnerability: Impact on Timolol Maleate Distribution
The recall of 176,784 bottles of Timolol Maleate Ophthalmic Solution USP, 0.5%, distributed nationwide in the U.S.A., exposes significant vulnerabilities within the pharmaceutical supply chain. For procurement directors, the immediate challenge is to identify and qualify alternative sources for Timolol Maleate to prevent stockouts and ensure continuity of patient care. Given the specialized nature of ophthalmic solutions, the pool of readily available, FDA-approved alternative manufacturers may be limited, potentially leading to supply shortages and price volatility. This situation mandates a proactive approach to supplier diversification and risk assessment, extending beyond raw material sourcing to encompass finished product packaging and delivery. Regulatory affairs heads must navigate the complexities of managing product returns, communicating with the FDA regarding the recall's progress, and ensuring that any replacement products meet all regulatory standards. The defective container issue, preventing medication dispensing, directly impacts patient safety and product efficacy, demanding meticulous oversight. Furthermore, business development executives should evaluate the reputational impact on both FDC Limited and its U.S. distributor, Rising Pharmaceuticals Inc. This incident could erode prescriber and patient confidence, potentially shifting market share to competitors with more robust quality control systems. Companies must assess their exposure to similar packaging-related risks across their product portfolios and implement more stringent quality control checkpoints throughout their supply networks.
FDC Limited's Regulatory Compliance Record: A Pattern of Recalls
This current Class II recall for Timolol Maleate Ophthalmic Solution USP, 0.5%, is not an isolated incident for FDC Limited. ChemLifeIntel's intelligence indicates a prior recall event on May 15, 2024, for the *same product* and due to a *similar container defect*, specifically highlighting supply chain risks related to container integrity. This recurring issue, involving the identical molecule and defect type, suggests a systemic quality control deficiency at FDC Limited's Aurangabad facility rather than an isolated manufacturing error. For regulatory affairs heads, this pattern elevates the risk profile of FDC Limited as a supplier, demanding heightened scrutiny of their corrective and preventive actions (CAPA) plans. Despite FDC Limited's overall 'low' risk band classification in our knowledge graph, this repeated failure in product packaging, directly impacting patient access to medication, challenges that assessment. Procurement directors must re-evaluate their supplier risk matrices, considering not just the initial qualification but also ongoing compliance and quality performance trends. A pattern of recalls, even if voluntary and Class II, can signal underlying issues that may eventually lead to more severe regulatory actions by the FDA, such as Warning Letters or Import Alerts, which would significantly disrupt supply. Business development executives should consider the long-term implications of such a compliance record on FDC's ability to secure new contracts or maintain existing market presence, particularly in highly regulated markets like the U.S.
Immediate Actions and Future Regulatory Scrutiny for FDC Limited
The voluntary, firm-initiated recall by FDC Limited for its Timolol Maleate Ophthalmic Solution is currently ongoing. This status means that the FDA is actively monitoring the effectiveness of the recall and FDC's adherence to regulatory requirements. For supply chain VPs, it is imperative to ensure that all affected product lots (083K063 and 083I091) are promptly removed from circulation and accounted for, minimizing further risk to patients and commercial exposure. The FDA will expect a thorough investigation into the root cause of the defective container issue and robust corrective actions to prevent recurrence. Given the prior recall for the same product and defect, FDC Limited faces increased regulatory scrutiny. While the current event is a recall, a persistent pattern of quality failures could escalate to more severe FDA enforcement actions, including the issuance of a Warning Letter or even an Import Alert, which would effectively block future shipments of products from the Aurangabad facility into the U.S. For procurement and regulatory teams, this necessitates a proactive engagement with FDC Limited to demand transparency on their remediation plan, including specific timelines and verification methods. Companies sourcing from FDC must prepare contingency plans for potential future supply disruptions and reassess the long-term viability of FDC as a reliable manufacturing partner for critical ophthalmic drugs.